Medibase
EN VI JA
Circular 44/2026/TT-BYT: bioequivalence deadline for registered generics moved to 1 November 2028
Medicine

Circular 44/2026/TT-BYT: bioequivalence deadline for registered generics moved to 1 November 2028

The Ministry of Health has amended Circular 07/2022/TT-BYT. Registered generics that fall under the bioequivalence (BE) requirement now have until 1 November 2028 — not 1 November 2026 — to be published as having BE evidence; after that date they can no longer be made, imported or renewed without it. The circular took effect on 1 November 2026. Separately, the Drug Administration of Vietnam published its batch 4 list for 2026: 45 drugs with proven bioequivalence (Decision 1003/QD-QLD, 9 November 2026).

In short

The Ministry of Health has given holders of registered generic medicines two more years to prove bioequivalence. Under the original Circular 07/2022/TT-BYT, registered generics that fall under the BE requirement had to be published as "drugs with bioequivalence evidence" within 48 months of 1 November 2022 — that is, by 1 November 2026. Circular 44/2026/TT-BYT, effective on that same day, replaces this with a fixed date of 1 November 2028 and spells out what happens to products that miss it. A week later the Drug Administration of Vietnam published another batch of the BE list: 45 drugs under Decision 1003/QD-QLD.

The two documents

  • Circular 44/2026/TT-BYT of the Minister of Health, dated 1 November 2026 and signed by Deputy Minister Do Xuan Tuyen. It amends Circular 07/2022/TT-BYT, which sets out which generic medicines must submit BE study data for marketing authorisation in Vietnam and what the BE dossier must contain. The circular has three articles: Article 1 rewrites Article 14(3) (the roadmap for registered drugs), Article 2 adds to Article 17 (responsibilities), and Article 3 sets the effective date. It is issued under the Pharmacy Law as amended by Law 44/2024/QH15 and Decree 163/2025/ND-CP.
  • Decision 1003/QD-QLD of the Drug Administration of Vietnam, dated 9 November 2026: the list of drugs with proven bioequivalence, batch 4 of 2026, with 45 drugs. It takes effect on signing.

The Ministry has also issued a consolidated text of Circular 07/2022/TT-BYT that incorporates the amendments.

What changes (Article 1 — new Article 14(3))

From 1 November 2028, a registered generic that contains an active substance or uses a dosage form for which BE testing is required under Circular 07/2022/TT-BYT:

  • Supply: may only continue to be manufactured, imported and placed on the market once it has been published as a drug with BE evidence (Article 14(3)(a)).
  • Stock already made or shipped: batches manufactured in Vietnam, and imported batches delivered at the port of loading in the exporting country, before 1 November 2028 may stay on the market until their expiry date (Article 14(3)(a)).
  • Renewal: a marketing authorisation will only be renewed for a drug whose BE evidence meets the requirements. Where a company has filed both a renewal and a request to classify the drug as having BE evidence, the two files are handled together (Article 14(3)(b)).
  • Procedure: publication follows Articles 47 and 55 of Circular 32/2026/TT-BYT on drug registration (Article 14(3)(c)).

The old Article 14(3) only said that registered drugs in scope "must be published" as having BE evidence after 48 months, and referred the procedure to the registration circular. It did not spell out the supply ban, the stock carve-out or the link to renewal.

New transparency duties (Article 2 — Article 17)

  • DAV list of drugs still without BE evidence: from 1 July 2027 the Drug Administration of Vietnam will publish and update, on its website, a list of drugs that have not yet been published as having BE evidence (new Article 17(1)(d)).
  • Company websites: organisations and individuals that hold the generics in question are responsible under Article 98(2) of the Pharmacy Law and must post on their own website the list of their drugs that have, or have not yet, been published as having BE evidence under the roadmap (new Article 17(1a)).

The rest of the roadmap is unchanged: since 1 November 2022, new applications for generics in scope (immediate-release and enteric-coated forms containing a substance in Annex I, and other modified-release forms) must include BE data (Article 14(1)); from 1 November 2025 (36 months), all enteric-coated modified-release generics need a BE section in new applications (Article 14(2)).

Effective date and transition

  • Circular 44/2026/TT-BYT took effect on 1 November 2026 (Article 3) — the same day the original 48-month deadline would have expired.
  • The circular contains no other transitional provisions. The transitional rules in Article 15 of Circular 07/2022/TT-BYT (e.g. dossiers filed before 1 November 2022 must still meet Article 14(3) after approval) are unchanged.
  • Context (secondary sources, not checked against the letters themselves): Official Letter 2042/QLD-DK of the Drug Administration of Vietnam (2 June 2026) asked registration holders to follow the roadmap and to report products for which they would not file BE publication requests; Official Letter 2595/QLD-DK (6 July 2026) asked for a report on how the roadmap was being implemented.

Decision 1003/QD-QLD: batch 4 of the BE list

  • What it is: the Drug Administration of Vietnam periodically publishes lists of "drugs with proven bioequivalence". Publication on such a list is how a registered generic meets the roadmap above. Decision 1003/QD-QLD adds 45 drugs, based on conclusions of the drug-registration advisory council (rounds 129 and 130, and the variation part of round 131).
  • What is in it: all 45 products are made abroad; 30 by manufacturers in India, the rest in China, Canada, Turkey, Hungary, Slovenia, South Korea, Bangladesh, Spain and Finland. Many are modified-release forms (metoprolol succinate, gliclazide MR, metformin and sodium valproate prolonged-release, tolterodine). Others include palbociclib 75/100/125 mg capsules, rivaroxaban, tacrolimus, ticagrelor, telmisartan with or without hydrochlorothiazide, and esomeprazole.
  • Where to find it: the annex in the signed PDF on dav.gov.vn lists each product's name, active substance and strength, dosage form, pack size, registration number, manufacturer and site address. You can check a registration number against Medibase's drug-registration search.
  • Who it is addressed to: provincial Departments of Health, pharmaceutical businesses and the holders of the listed drugs. Copies go to Vietnam Social Security, the National Centralized Drug Procurement Centre and hospitals under the Ministry of Health.
  • Why it matters for tenders: neither text mentions tendering. But under Vietnam's separate drug-procurement rules, BE evidence is one of the criteria used to place generics in tender groups (see Medibase's tendering guide). Being on a published BE list is the evidence buyers check.

What companies should do

  • Map your portfolio: list registered generics that contain an Annex I substance or are modified-release, and check which ones are already on a published BE list.
  • Plan to 1 November 2028: for products not yet listed, file BE classification requests early. Combine them with renewals that fall due, since the two files are handled together.
  • Supply planning: importers should note that the cut-off for imports is delivery at the port of loading before 1 November 2028. Batches shipped later cannot be imported without BE publication.
  • Website disclosure: prepare a page listing which of your drugs have, or do not yet have, BE publication. The circular does not set a separate deadline for this.
  • Watch 1 July 2027: from then on the DAV's list of drugs without BE evidence will be public. Hospitals and tender buyers are likely to use it.

What is not clear yet

  • Company disclosure deadline: Article 17(1a) gives no date or format for the company-website list.
  • Article 98(2) of the Pharmacy Law: the circular cross-refers to it without restating it. Check the current amended text.
  • Grandfathered stock: how the "delivered at the port of loading" date will be evidenced at import (e.g. bill of lading) is not specified.
  • Pending files: for files pending at the DAV on 1 November 2028, the circular covers only renewal plus BE classification filed together. It says nothing about a classification request filed on its own.

Sources

Services by MTC

Need help with drug registration or pharmacovigilance?

Handled by MTC Consulting & Trading Co., Ltd, the team behind Medibase — medibase@mtcorp.vn

Related articles — Medicine

Back to news listing

Reference information only; not legal or medical advice.